A multi-institutional group led by the University of California at San Francisco’s Quantitative Biosciences Institute (QBI) has identified more than 200 host proteins that interacted with SARS-CoV-2 viral proteins during infection, creating “a blueprint of how SARS-CoV-2 hijacks human cells,” QBI Director Nevan Krogan told reporters. They then used that blueprint to identify 10 drugs, some FDA approved and some in clinical trials, that were able to inhibit viral growth in cell culture assays, marking them for further study as potential antivirals. The work also identified one compound, dextromethorphan, that appeared to facilitate viral growth.
How U.S. health care emerges from the COVID-19 pandemic is a million-dollar question, as patients, providers, payers and drug manufacturers are adapting to a new reality that’s advancing telehealth and changing how providers interact with patients.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acasti, Akarx, Alpha Cognition, Annovis Bio, Banner Life Sciences, Biocardia, Dova, Galectin, Genmab, Glaxosmithkline, Inmed, Junshi, Marker, Medivir, Neon, Pharming, Seelos, Zentalis.
Artificial intelligence-focused Chronolife SAS, of Paris, has secured class IIa medical certification from the EU for its smart T-shirt, which has the new brand name Keesense. The reusable, washable T-shirt is designed for comfortable, round-the-clock use. It works by transmitting data to a paired smartphone app via Bluetooth.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Diatherix, Medtronic, Photopharmics, Psychemedics, Senseonics, Vuno.